1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6569C815D94AE229800258B0A0029230F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/establishing-latam-standards-field-medical-performance-excellence?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing LATAM Standards for Field Medical Performance Excellence

ID: 5802


Features:

9 Info Graphics

19 Data Graphics

310+ Metrics

9 Narratives


Pages/Slides: 33


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing LATAM Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

With diverse regulatory environments and varying healthcare infrastructures across countries, manufacturers in the Latin America (LATAM) region need tailored approaches to improve the efficiency of their field medical teams.

Best Practices, LLC conducted benchmarking research to equip field medical leaders with requisite knowledge and tactics to drive performance excellence across Latin America. The study explores strategic insights to enhance KOL interactions, assess MSL performance, and strategically align staffing footprints.


KEY TOPICS

  • Effective Field Performance Metrics in the LATAM Region
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in the LATAM Region
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • LATAM Region Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in the LATAM Region

KEY METRICS

  • Average number of tiered vs. non-tiered KOLs per MSL in the LATAM region
  • Monthly KOL and F2F interactions in the LATAM region
  • MSL’s average time spent in each thought leader interaction in the LATAM region
  • Weighting criteria for various interaction types on the MSL scorecard – LATAM region
  • Optimal and widely utilized field metrics for assessing and showcasing MSL impact in the LATAM region
  • Metrics for engaging non-tiered KOLs in the LATAM region
  • Average MSL time in the field (days per year) in the LATAM region
  • Percentage of MSL time spent on external, internal and logistics activities in the LATAM region
  • Weekly MSL time allocation on each activity stream in the LATAM region
  • Percentage of overall targets that can be classified as KOLs, HCPs, payers, or other external stakeholders in the LATAM region
  • LATAM region field medical staffing footprint
  • Span of control: Number of MSLs per MSL manager in the LATAM region

SAMPLE KEY FINDINGS

  • Time Allocation Breakdown: In LATAM, MSLs dedicate approximately 70% of their work time to external engagements. Internal tasks and logistics activities consume 14% and 19% of MSL time, respectively.

METHODOLOGY

This study offers tailored benchmarks and insights focused on the LATAM region. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from over 100 biopharma manufacturers across the world. The data is meticulously segmented at the regional level to offer nuanced insights.


Additionally, Best Practices, LLC utilizes its proprietary Field Medical Excellence database to provide additional benchmarks tailored to align with varied portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.